Alcon raises 2026 earnings growth outlook on positive Q2 results

Alcon has reported Q2 revenues of astir $2.8bn, indicative of an 8% uptick year-over-year (YoY), prompting it to revise its 2026 outlook.

The Swiss eyecare specializer present expects 2026 net maturation to onshore successful the 12% to 15% per diluted stock range, up from 10% to 13% previously. Alcon is maintaining its YoY income maturation outlook wrong the 5% to 7% range.

The lion's stock of Alcon's profits came from its surgical conception astatine astir $1.6bn, indicative of an 8% uptick YoY, with imaginativeness attraction successful 2nd spot with income of astir $1.2bn corresponding to an summation of 8% compared to the aforesaid 4th past year.

Delving deeper into its Q2 performance, Alcon highlighted that operating income of $11m successful Q2 versus $247m YoY was offset by its determination to discontinue the intraocular lens (IOL) programmes it acquired from PowerVision successful March 2019. As portion of this decision, the institution recorded a pre-tax complaint of $402m successful Q2.

Alcon elected to discontinue the PowerVision programmes pursuing investigation of the latest objective survey data, stating that they did not nutrient "acceptable diligent outcomes", with this decision chiefly based connected "persistent unpredictable post-surgical ocular outcomes" reported successful a subset of the patients that could not beryllium resolved contempt aggregate improvement efforts.

Alcon released its financials aft markets closed connected 10 August. Ahead of marketplace unfastened connected 11 August, the company's shares connected the New York Stock Exchange (NYSE) were up by astir 2% (correct arsenic of 5:08am ET) astatine $75.10 versus $73.63 previously. Alcon has a marketplace headdress of $30.29bn.

Alcon's CEO, David Endicott, said the company's Q2 show was driven by "strong execution" and a raft of caller merchandise launches, including its PanOptix Pro trifocal IOL successful April 2025.

Endicott said: "Across the portfolio, our innovative products proceed to summation traction and grow our marketplace positions, including interaction lenses wherever we are continuing to summation share.

"With a robust pipeline and respective important launches ahead, we are good positioned to present sustainable semipermanent maturation and further fortify our enactment successful oculus care."

Alcon's show follows a Q1 successful which its planned acquisition of STAAR Surgical fell through. Originally tabling $1.6bn to get the company, the plans were subsequently scrapped pursuing a disputatious play betwixt STAAR and its shareholders.

"Alcon raises 2026 net maturation outlook connected affirmative Q2 results" was primitively created and published by Medical Device Network, a GlobalData owned brand.